SynAct Pharma AB SYNACT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 7.00
- Day Range
- SEK 6.95–7.03
- 52-Week Range
- SEK 4.98–124.60
- Bid/Ask
- SEK 7.00 / SEK 7.03
- Market Cap
- SEK 289.08 Mil
- Volume/Avg
- 34,961 / 134,515
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 5
- Website
- https://www.synactpharma.se
Comparables
Valuation
Metric
|
SYNACT
|
HNSA
|
CALTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.63 | — | 92.38 |
Price/Sales | — | 16.63 | 8.47 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
SYNACT
|
HNSA
|
CALTX
|
---|---|---|---|
Quick Ratio | 2.29 | 2.57 | 2.62 |
Current Ratio | 2.31 | 2.66 | 2.69 |
Interest Coverage | −295.12 | −7.14 | −7.32 |
Quick Ratio
SYNACT
HNSA
CALTX
Profitability
Metric
|
SYNACT
|
HNSA
|
CALTX
|
---|---|---|---|
Return on Assets (Normalized) | −43.49% | −71.82% | −31.48% |
Return on Equity (Normalized) | −55.44% | — | −164.82% |
Return on Invested Capital (Normalized) | −54.89% | −85.22% | −40.72% |
Return on Assets
SYNACT
HNSA
CALTX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Vertex Pharmaceuticals Inc
VRTX
| Szsrtvdhv | Dtmzbn | $124.3 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Ngbmlydtg | Thfjhm | $111.3 Bil | |||
Moderna Inc
MRNA
| Mlltyhy | Vgl | $56.9 Bil | |||
BioNTech SE ADR
BNTX
| Zccgykxr | Vkc | $24.2 Bil | |||
argenx SE ADR
ARGX
| Ckwjwkx | Yllzl | $22.5 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Clfjmfgl | Jrbczhm | $19.8 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Pnphrplh | Myvdkn | $15.3 Bil | |||
Incyte Corp
INCY
| Dmbyxvvw | Ncqgh | $13.4 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Xvtzkckrv | Qnksjz | $12.4 Bil | |||
United Therapeutics Corp
UTHR
| Bbfsqvl | Rzz | $12.2 Bil |